Stockscreener 앱 받기
3.90
9.30%
-0.40
시장 영업 전:
2.40
-1.50
-38.46%
Enveric Biosciences Inc 주식(ENVB)의 최신 뉴스
Enveric Biosciences stock plummets after pricing $5M capital raise - MSN
Biotech Funding Alert: Enveric Secures $5M to Advance Neural Therapeutics Pipeline - StockTitan
Enveric Biosciences Announces Pricing of $5 Million Public Offering - Business Wire
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office - BioSpace
Enveric Passes Key Milestone on Patent Path for Mental-Health Treatment - MarketWatch
Enveric Biosciences stock hits 52-week low at $0.29 By Investing.com - Investing.com South Africa
Enveric Biosciences stock hits 52-week low at $0.29 - MSN
Jay Pharma Inc. Announces Appointment of Sara Dakar as Vice President, Product Development - Marketscreener.com
AMERI Holdings, Inc. Announces Executive Changes -April 08, 2019 at 08:00 am EDT - Marketscreener.com
AMERI Holdings, Inc. Announces Board Changes -December 12, 2018 at 06:59 am EST - Marketscreener.com
R. James Woolsey Joins AMERI Holdings as Strategy Consultant -January 27, 2020 at 08:00 am EST - Marketscreener.com
Ameri Holdings, Inc. Approves Director Changes -August 17, 2018 at 08:00 am EDT - Marketscreener.com
Ameri Holdings, Inc. Announces Board Changes -April 02, 2019 at 04:01 pm EDT - Marketscreener.com
Robert Wilkins Joins Jay Pharma as Chief Medical Officer -July 29, 2020 at 09:00 am EDT - Marketscreener.com
Enveric Biosciences Appoints Arash Asher to Scientific Advisory Board -May 12, 2021 at 07:30 am EDT - Marketscreener.com
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders - Marketscreener.com
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally - Marketscreener.com
Enveric Biosciences Announces 1-for-15 Reverse Stock Split - MSN
Enveric Biosciences Announces 1-for-15 Reverse Stock Split By Investing.com - Investing.com UK
Analyzing Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA) - Defense World
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025” - BioSpace
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8 - Business Wire
Enveric Biosciences CEO to Present Future of Psychedelics Vision at Major JP Morgan Week Events - StockTitan
Enveric Biosciences to Release Investor Presentation - TipRanks
ENVB Stock Touches 52-Week Low at $0.3 Amid Market Challenges - Investing.com Nigeria
Enveric Biosciences (NASDAQ:ENVB) Shares Down 4.6% – Here’s Why - Defense World
Enveric Biosciences Receives Two US Patents for Psilocybin Derivatives - Microdose Psychedelic Insights
Enveric Biosciences secures patents for neuroplasticity drugs By Investing.com - Investing.com Canada
Enveric Biosciences Expands Patent Portfolio for Novel Psilocybin Compounds - StockTitan
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds - Yahoo Finance
Enveric advances neuroplastogen EB-003 through PK studies - BioWorld Online
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results - Benzinga
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior - Business Wire
Enveric Biosciences faces potential Nasdaq delisting By Investing.com - Investing.com Nigeria
Enveric Biosciences faces potential Nasdaq delisting - Investing.com India
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders - Benzinga
atai Life Sciences and Enveric Biosciences Report Q3 2024 Results - Microdose Psychedelic Insights
Enveric Biosciences narrows net loss, advances lead drug candidate - Green Market Report
Enveric Biosciences Inc (ENVB) Quarterly 10-Q Report - Quartzy
Enveric Biosciences Narrows Q3 Loss, Advances Mental Health Drug Development | ENVB Stock News - StockTitan
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results - Business Wire
Enveric Biosciences licenses drug candidate to MycoMedica By Investing.com - Investing.com Australia
Enveric and MycoMedica’s New Licensing Agreement Marks a Strategic Shift in Mental Health Treatment - Microdose Psychedelic Insights
Enveric Biosciences licenses drug candidate to MycoMedica - Investing.com India
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 - BioSpace
Enveric inks $62M licensing deal for psilocin prodrug - Green Market Report
5.49%
0.79%
자본화:
|
볼륨(24시간):